DOSAGE FORMS & STRENGTHS SECTION.

3 DOSAGE FORMS AND STRENGTHS. Capsule: 667 mg calcium acetate, USP per capsule.

ADVERSE REACTIONS SECTION.

6 ADVERSE REACTIONS. Hypercalcemia is discussed elsewhere see Warnings and Precautions (5.1)] 6.1 Clinical Trial ExperienceBecause clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In clinical studies, calcium acetate has been generally well tolerated.Calcium acetate was studied in 3-month, open-label, non-randomized study of 98 enrolled ESRD hemodialysis patients and an alternate liquid formulation of calcium acetate was studied in two-week double-blind, placebo-controlled, cross-over study with 69 enrolled ESRD hemodialysis patients. Adverse reactions (>2% on treatment) from these trials are presented in Table 1.Table 1: Adverse Reactions in Patients with End-Stage Renal Disease Undergoing HemodialysisPreferred Term Total adverse reactions reported for calcium acetaten=167 (%) 3-mo, open- label study of calcium acetaten=98 (%) Double blind, placebo-controlled, cross-over study of liquid calcium acetaten=69Calcium acetate (%) Placebo (%) Nausea6 (3.6)6 (6.1)0 (0.0)0 (0.0)Vomiting4 (2.4)4 (4.1)0 (0.0)0 (0.0)Hypercalcemia21 (12.6)16 (16.3)5 (7.2)0 (0.0)Mild hypercalcemia may be asymptomatic or manifest itself as constipation, anorexia, nausea, and vomiting. More severe hypercalcemia is associated with confusion, delirium, stupor, and coma. Decreasing dialysate calcium concentration could reduce the incidence and severity of calcium acetate-induced hypercalcemia. Isolated cases pruritus have been reported, which may represent allergic reactions.6.2 Post marketing ExperienceBecause these reactions are reported voluntarily from population of uncertain size, it is not always possible to estimate their frequency or to establish causal relationship to drug exposure. The following additional adverse reactions have been identified during postapproval of calcium acetate: dizziness, edema, and weakness.

CLINICAL PHARMACOLOGY SECTION.

12 CLINICAL PHARMACOLOGY. Patients with ESRD retain phosphorus and can develop hyperphosphatemia. High serum phosphorus can precipitate serum calcium resulting in ectopic calcification. Hyperphosphatemia also plays role in the development of secondary hyperparathyroidism in patients with ESRD.12.1 Mechanism of ActionCalcium acetate, when taken with meals, combines with dietary phosphate to form an insoluble calcium phosphate complex, which is excreted in the feces, resulting in decreased serum phosphorus concentration. 12.2 PharmacodynamicsOrally administered calcium acetate from pharmaceutical dosage forms is systemically absorbed up to approximately 40% under fasting conditions and up to approximately 30% under non-fasting conditions. This range represents data from both healthy subjects and renal dialysis patients under various conditions.

CLINICAL STUDIES SECTION.

14 CLINICAL STUDIES. Effectiveness of calcium acetate in decreasing serum phosphorus has been demonstrated in two studies of the calcium acetate solid oral dosage form.Ninety-one patients with end-stage renal disease who were undergoing hemodialysis and were hyperphosphatemic (serum phosphorus >5.5 mg/dL) following 1-week phosphate binder washout period contributed efficacy data to an open-label, non-randomized study.The patients received calcium acetate 667 mg tablets at each meal for period of 12 weeks. The initial starting dose was tablets per meal for meals day, and the dose was adjusted as necessary to control serum phosphorus levels. The average final dose after 12 weeks of treatment was 3.4 tablets per meal. Although there was decrease in serum phosphorus, in the absence of control group the true magnitude of effect is uncertain.The data presented in Table demonstrate the efficacy of calcium acetate in the treatment of hyperphosphatemia in end-stage renal disease patients. The effects on serum calcium levels are also presented.Table 2: Average Serum Phosphorous and Calcium Levels at Pre-Study, Interim, and Study Completion Time pointsParameterPre-StudyWeek b Week 8Week 12p-value Phosphorous (mg/dL) 7.4 +- 0.175.9 +- 0.165.6 +- 0.175.2 +- 0.17<=0.01Calcium8.9 +- 0.099.5 +- 0.109.7 +- 0.109.7 +- 0.10<=0.01a Values expressed as mean +- SE. Ninety-one patients completed at least weeks of the study. ANOVA of difference in values at pre-study and study completion. There was 30% decrease in serum phosphorus levels during the 12-week study period (p<0.01). Two-thirds of the decline occurred in the first month of the study. Serum calcium increased 9% during the study mostly in the first month of the study.Treatment with the phosphate binder was discontinued for patients from the open-label study, and those patients whose serum phosphorus exceeded 5.5 mg/dL were eligible for entry into double-blind, placebo-controlled, cross-over study. Patients were randomized to receive calcium acetate or placebo, and each continued to receive the same number of tablets as had been individually established during the previous study. Following weeks of treatment, patients switched to the alternative therapy for an additional weeks.The phosphate binding effect of calcium acetate is shown in the Table 3. Table 3: Serum Phosphorous and Calcium Levels at Study Initiation and After Completion of Each Treatment ArmParameterPre-StudyPost Treatmentp-value Calcium AcetatePlaceboPhosphorous (mg/dL) 7.3 +- 0.185.9 +- 0.247.8 +- 0.22<0.01Calcium (mg/dL)a8.9 +- 0.119.5 +- 0.138.8 +- 0.12<0.01a Values expressed as mean +- SEM ANOVA of calcium acetate vs. placebo after weeks of treatment. Overall, weeks of treatment with calcium acetate statistically significantly (p<0.01) decreased serum phosphorus by mean of 19% and increased serum calcium by statistically significant (p<0.01) but clinically unimportant mean of 7%.

CONTRAINDICATIONS SECTION.

4 CONTRAINDICATIONS. Patients with hypercalcemia.

DESCRIPTION SECTION.

11 DESCRIPTION. Calcium acetate, USP acts as phosphate binder. Its chemical name is Calcium acetate, USP. Its molecular formula is 4H 6CaO 4, and its molecular weight is 158.17. Its structural formula is: Each opaque capsule with blue cap and white body is spin printed in blue and white ink with SUVEN printed on the cap and 667 printed on the body. Each capsule contains 667 mg calcium acetate, USP (anhydrous; Ca(CH 3COO) 2; MW=158.17 grams) equal to 169 mg (8.45 mEq) calcium, and water as the inert binder, crospovidone and sodium stearyl fumarate The gelatin cap and body have the following inactive ingredients: FD&C blue 1, D&C red 28, titanium dioxide and gelatin. Imprinting ink on capsule body contains shellac and FD&C Aluminum Lake and imprinting ink on capsule cap contains shellac, titanium dioxide and potassium hydroxide. Calcium acetate capsules are administered orally for the control of hyperphosphatemia in end-stage renal failure. Meets USP Dissolution Test . Structure.

DOSAGE & ADMINISTRATION SECTION.

2 DOSAGE AND ADMINISTRATION. The recommended initial dose of calcium acetate capsules for the adult dialysis patient is capsules with each meal. Increase the dose gradually to lower serum phosphorus levels to the target range, as long as hypercalcemia does not develop. Most patients require to capsules with each meal.

DRUG INTERACTIONS SECTION.

7 DRUG INTERACTIONS. The drug interaction of calcium acetate is characterized by the potential of calcium to bind to drugs with anionic functions (e.g., carboxyl, and hydroxyl groups). Calcium acetate may decrease the bioavailability of tetracyclines or fluoroquinolones via this mechanism.There are no empirical data on avoiding drug interactions between calcium acetate and most concomitant drugs. When administering an oral medication with calcium acetate where reduction in the bioavailability of that medication would have clinically significant effect on its safety or efficacy, administer the drug one hour before or three hours after calcium acetate. Monitor blood levels of the concomitant drugs that have narrow therapeutic range. Patients taking anti-arrhythmic medications for the control of arrhythmias and anti-seizure medications for the control of seizure disorders were excluded from the clinical trials with all forms of calcium acetate.7.1 CiprofloxacinIn study of 15 healthy subjects, co-administered single dose of calcium acetate tablets, approximately 2.7g, decreased the bioavailability of ciprofloxacin by approximately 50%.

HOW SUPPLIED SECTION.

16 HOW SUPPLIED/STORAGE AND HANDLING. Calcium Acetate capsules USP, 667 mg are hard gelatin capsules with blue opaque cap imprinted with SUVEN in white color ink and white opaque body imprinted with 667 blue color ink. Each capsule contains 667 mg calcium acetate (anhydrous Ca(CH 3COO) 2; MW=158.17 grams) equal to 169 mg (8.45 mEq) calcium. NDC 16571-813-20 Bottles of 200 with child-resistant closure. STORAGE. Store at 20-25C (68-77F); excursions permitted to 15 to 30C (59 to 86F) [See USP Controlled Room Temperature].

INDICATIONS & USAGE SECTION.

1 INDICATIONS AND USAGE. Calcium acetate is phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (ESRD).

NONCLINICAL TOXICOLOGY SECTION.

13 NONCLINICAL TOXICOLOGY. 13.1 Carcinogenesis, Mutagenesis, Impairment of FertilityNo carcinogenicity, mutagenicity, or fertility studies have been conducted with calcium acetate.

OVERDOSAGE SECTION.

10 OVERDOSAGE. Administration of calcium acetate in excess of the appropriate daily dosage may result in hypercalcemia see Warnings and Precautions (5.1)].

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL.

Calcium Acetate Capsules USP. Rising Pharmaceuticals NDC 16571-813-20Calcium AcetateCapsules USP667 mg200 Capsules Rx OnlyEach capsule contains: 667 mg calcium acetate, USP equivalent to 169 mg calciumDIRECTIONS: SWALLOW CAPSULE. DO NOT CHEW. Take as directed by your physician.KEEP THIS AND ALL DRUGS OUT OF REACHOF CHILDREN.Store at 20 to 25C (68 to 77F); excursionspermitted to 15 to 30C (59 to 86F) [See USPControlled Room Temperature].Manufactured By:Suven Pharmaceuticals Limited Pashamylaram, Telangana, 502307, India M.L No.: 24/MD/AP/2009/F/CCDistributed By: Rising Pharma Holdings, Inc. East Brunswick, NJ, 08816 Lb50318-1-00 Rev. 08/2021 Label.

PATIENT COUNSELING INFORMATION.

17 PATIENT COUNSELING INFORMATION. Inform patients to take calcium acetate capsules with meals, adhere to their prescribed diets, and avoid the use of calcium supplements including nonprescription antacids. Inform the patients about the symptoms of hypercalcemia see Warnings and Precautions (5.1) and Adverse Reactions (6.1)]. Advise patients who are taking an oral medication where reduction in the bioavailability of that medication would have clinically significant effect on its safety or efficacy to take the drug one hour before or three hours after calcium acetate capsules.

SPL PATIENT PACKAGE INSERT SECTION.

These highlights do not include all the information needed to use CALCIUM ACETATE CAPSULES safely and effectively. Please see full prescribing information for CALCIUM ACETATE CAPSULES. CALCIUM ACETATE capsules, for oral use Initial U.S. Approval: 1990. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CALCIUM ACETATE CAPSULES safely and effectively. See full prescribing information for CALCIUM ACETATE CAPSULES.CALCIUM ACETATE capsules, for oral use Initial U.S. Approval: 1990 --------------------INDICATIONS AND USAGE---------------Calcium acetate is phosphate binder indicated for the reduction of serum phosphorus in patients with end stage renal disease.(1)---------------DOSAGE AND ADMINISTRATION-----------Starting dose is capsules with each meal.(2)Titrate the dose every to weeks until acceptable serum phosphorus level is reached. Most patients require to capsules with each meal.(2)---------------DOSAGE FORMS AND STRENGTHS--------Capsule: 667 mg calcium acetate capsule.(3)--------------------CONTRAINDICATIONS---------------------Hypercalcemia.(4)------------------WARNINGS AND PRECAUTIONS-------------Treat mild hypercalcemia by reducing or interrupting calcium acetate and Vitamin D. Severe hypercalcemia may require hemodialysis and discontinuation of calcium acetate.(5.1)Hypercalcemia may aggravate digitalis toxicity.(5.2)-------------------------ADVERSE REACTIONS--------------------The most common (> 10%) adverse reactions are hypercalcemia, nausea and vomiting.(6.1)In clinical studies, patients have occasionally experienced nausea during calcium acetate therapy.(6)To report SUSPECTED ADVERSE REACTIONS, contact SUVEN PHARMACEUTICALS LIMITED at 1-855-642-2594 or Rising Pharma Holdings, Inc. at 1-866-562-4597 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch--------------DRUG INTERACTIONS---------------------Calcium acetate may decrease the bioavailability of tetracyclines or fluoroquinolones.(7)When clinically significant drug interactions are expected, administer the drug at least one hour before or at least three hours after calcium acetate or consider monitoring blood levels of the drug.(7)See 17 for PATIENT COUNSELING INFORMATIONRevised: 08/2021FULL PRESCRIBING INFORMATION: CONTENTS1 INDICATIONS AND USAGE2 DOSAGE AND ADMINISTRATION DOSAGE FORMS AND STRENGTHS CONTRAINDICATIONS WARNINGS AND PRECAUTIONS 5.1 Hypercalcemia 5.2 Concomitant Use with Medications ADVERSE REACTIONS6.1 Clinical Trials Experience 6.2 Post marketing Experience DRUG INTERACTIONS7.1 Ciprofloxacin8 USE IN SPECIFIC POPULATIONS8.1 Pregnancy 8.2 Labor and Delivery 8.3 Nursing Mothers 8.4 Pediatric Use8.5 Geriatric Use10 OVERDOSAGE11 DESCRIPTION12 CLINICAL PHARMACOLOGY12.1 Mechanism of Action12.2 Pharmacodynamics13 NONCLINICAL TOXICOLOGY13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility14 CLINICAL STUDIES15 HOW SUPPLIED/STORAGE AND HANDLING17 PATIENT COUNSELING INFORMATIONSections or subsections omitted from the full prescribing information are not listed. Calcium acetate is phosphate binder indicated for the reduction of serum phosphorus in patients with end stage renal disease.(1). Starting dose is capsules with each meal.(2). Titrate the dose every to weeks until acceptable serum phosphorus level is reached. Most patients require to capsules with each meal.(2). Capsule: 667 mg calcium acetate capsule.(3). Hypercalcemia.(4). Treat mild hypercalcemia by reducing or interrupting calcium acetate and Vitamin D. Severe hypercalcemia may require hemodialysis and discontinuation of calcium acetate.(5.1). Hypercalcemia may aggravate digitalis toxicity.(5.2). The most common (> 10%) adverse reactions are hypercalcemia, nausea and vomiting.(6.1). In clinical studies, patients have occasionally experienced nausea during calcium acetate therapy.(6). Calcium acetate may decrease the bioavailability of tetracyclines or fluoroquinolones.(7). When clinically significant drug interactions are expected, administer the drug at least one hour before or at least three hours after calcium acetate or consider monitoring blood levels of the drug.(7). INDICATIONS AND USAGE. Calcium acetate is phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (ESRD).. DOSAGE AND ADMINISTRATION. The recommended initial dose of calcium acetate capsules for the adult dialysis patient is capsules with each meal. Increase the dose gradually to lower serum phosphorus levels to the target range, as long as hypercalcemia does not develop. Most patients require to capsules with each meal.. DOSAGE FORMS AND STRENGTHS. Capsule: 667 mg calcium acetate, USP per capsule.. CONTRAINDICATIONS. Patients with hypercalcemia.. WARNINGS AND PRECAUTIONS. 5.1 HypercalcemiaPatients with end stage renal disease may develop hypercalcemia when treated with calcium, including calcium acetate. Avoid the use of calcium supplements, including calcium based nonprescription antacids, concurrently with calcium acetate. An overdose of calcium acetate may lead to progressive hypercalcemia, which may require emergency measures. Therefore, early in the treatment phase during the dosage adjustment period, monitor serum calcium levels twice weekly. Should hypercalcemia develop, reduce the calcium acetate dosage, or discontinue the treatment, depending on the severity of hypercalcemia.More severe hypercalcemia (Ca >12 mg/dL) is associated with confusion, delirium, stupor and coma. Severe hypercalcemia can be treated by acute hemodialysis and discontinuing calcium acetate therapy.Mild hypercalcemia (10.5 to 11.9 mg/dL) may be asymptomatic or manifest as constipation, anorexia, nausea, and vomiting. Mild hypercalcemia is usually controlled by reducing the calcium acetate dose or temporarily discontinuing therapy. Decreasing or discontinuing Vitamin therapy is recommended as well.Chronic hypercalcemia may lead to vascular calcification and other soft-tissue calcification. Radiographic evaluation of suspected anatomical regions may be helpful in early detection of soft tissue calcification. The long-term effect of calcium acetate on the progression of vascular or soft tissue calcification has not been determined.Hypercalcemia (>11 mg/dL) was reported in 16% of patients in 3-month study of solid dose formulation of calcium acetate; all cases resolved upon lowering the dose or discontinuing treatment. Maintain the serum calcium-phosphorus (Ca P) product below 55 mg2/dL2. 5.2 Concomitant Use with MedicationsHypercalcemia may aggravate digitalis toxicity.. ADVERSE REACTIONS. Hypercalcemia is discussed elsewhere see Warnings and Precautions (5.1)] 6.1 Clinical Trial ExperienceBecause clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In clinical studies, calcium acetate has been generally well tolerated.Calcium acetate was studied in 3-month, open-label, non-randomized study of 98 enrolled ESRD hemodialysis patients and an alternate liquid formulation of calcium acetate was studied in two-week double-blind, placebo-controlled, cross-over study with 69 enrolled ESRD hemodialysis patients. Adverse reactions (>2% on treatment) from these trials are presented in Table 1.Table 1: Adverse Reactions in Patients with End-Stage Renal Disease Undergoing HemodialysisPreferred Term Total adverse reactions reported for calcium acetaten=167 (%) 3-mo, open- label study of calcium acetaten=98 (%) Double blind, placebo-controlled, cross-over study of liquid calcium acetaten=69Calcium acetate (%) Placebo (%) Nausea6 (3.6)6 (6.1)0 (0.0)0 (0.0)Vomiting4 (2.4)4 (4.1)0 (0.0)0 (0.0)Hypercalcemia21 (12.6)16 (16.3)5 (7.2)0 (0.0)Mild hypercalcemia may be asymptomatic or manifest itself as constipation, anorexia, nausea, and vomiting. More severe hypercalcemia is associated with confusion, delirium, stupor, and coma. Decreasing dialysate calcium concentration could reduce the incidence and severity of calcium acetate-induced hypercalcemia. Isolated cases pruritus have been reported, which may represent allergic reactions.6.2 Post marketing ExperienceBecause these reactions are reported voluntarily from population of uncertain size, it is not always possible to estimate their frequency or to establish causal relationship to drug exposure. The following additional adverse reactions have been identified during postapproval of calcium acetate: dizziness, edema, and weakness. 7 DRUG INTERACTIONS. The drug interaction of calcium acetate is characterized by the potential of calcium to bind to drugs with anionic functions (e.g., carboxyl, and hydroxyl groups). Calcium acetate may decrease the bioavailability of tetracyclines or fluoroquinolones via this mechanism.There are no empirical data on avoiding drug interactions between calcium acetate and most concomitant drugs. When administering an oral medication with calcium acetate where reduction in the bioavailability of that medication would have clinically significant effect on its safety or efficacy, administer the drug one hour before or three hours after calcium acetate. Monitor blood levels of the concomitant drugs that have narrow therapeutic range. Patients taking anti-arrhythmic medications for the control of arrhythmias and anti-seizure medications for the control of seizure disorders were excluded from the clinical trials with all forms of calcium acetate.7.1 CiprofloxacinIn study of 15 healthy subjects, co-administered single dose of calcium acetate tablets, approximately 2.7g, decreased the bioavailability of ciprofloxacin by approximately 50%. 8 USE IN SPECIFIC POPULATIONS. 8.1 PregnancyPregnancy Category CCalcium acetate capsules contains calcium acetate. Animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. Patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment see Warnings and Precautions (5.1)]. Maintenance of normal serum calcium levels is important for maternal and fetal well-being. Hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. Calcium acetate treatment, as recommended, is not expected to harm fetus if maternal calcium levels are properly monitored during and following treatment. 8.2 Labor and DeliveryThe effects of calcium acetate on labor and delivery are unknown. 8.3 Nursing MothersCalcium acetate is excreted in human milk. Human milk feeding by mother receiving calcium acetate is not expected to harm an infant, provided maternal serum calcium levels are appropriately monitored. 8.4 Pediatric UseSafety and effectiveness in pediatric patients have not been established. 8.5 Geriatric UseClinical studies of calcium acetate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. 10 OVERDOSAGE. Administration of calcium acetate in excess of the appropriate daily dosage may result in hypercalcemia see Warnings and Precautions (5.1)]. 11 DESCRIPTION. Calcium acetate, USP acts as phosphate binder. Its chemical name is Calcium acetate, USP. Its molecular formula is 4H 6CaO 4, and its molecular weight is 158.17. Its structural formula is: Each opaque capsule with blue cap and white body is spin printed in blue and white ink with SUVEN printed on the cap and 667 printed on the body. Each capsule contains 667 mg calcium acetate, USP (anhydrous; Ca(CH 3COO) 2; MW=158.17 grams) equal to 169 mg (8.45 mEq) calcium, and water as the inert binder, crospovidone and sodium stearyl fumarate The gelatin cap and body have the following inactive ingredients: FD&C blue 1, D&C red 28, titanium dioxide and gelatin. Imprinting ink on capsule body contains shellac and FD&C Aluminum Lake and imprinting ink on capsule cap contains shellac, titanium dioxide and potassium hydroxide. Calcium acetate capsules are administered orally for the control of hyperphosphatemia in end-stage renal failure. Meets USP Dissolution Test . Structure. 12 CLINICAL PHARMACOLOGY. Patients with ESRD retain phosphorus and can develop hyperphosphatemia. High serum phosphorus can precipitate serum calcium resulting in ectopic calcification. Hyperphosphatemia also plays role in the development of secondary hyperparathyroidism in patients with ESRD.12.1 Mechanism of ActionCalcium acetate, when taken with meals, combines with dietary phosphate to form an insoluble calcium phosphate complex, which is excreted in the feces, resulting in decreased serum phosphorus concentration. 12.2 PharmacodynamicsOrally administered calcium acetate from pharmaceutical dosage forms is systemically absorbed up to approximately 40% under fasting conditions and up to approximately 30% under non-fasting conditions. This range represents data from both healthy subjects and renal dialysis patients under various conditions. 13 NONCLINICAL TOXICOLOGY. 13.1 Carcinogenesis, Mutagenesis, Impairment of FertilityNo carcinogenicity, mutagenicity, or fertility studies have been conducted with calcium acetate. 14 CLINICAL STUDIES. Effectiveness of calcium acetate in decreasing serum phosphorus has been demonstrated in two studies of the calcium acetate solid oral dosage form.Ninety-one patients with end-stage renal disease who were undergoing hemodialysis and were hyperphosphatemic (serum phosphorus >5.5 mg/dL) following 1-week phosphate binder washout period contributed efficacy data to an open-label, non-randomized study.The patients received calcium acetate 667 mg tablets at each meal for period of 12 weeks. The initial starting dose was tablets per meal for meals day, and the dose was adjusted as necessary to control serum phosphorus levels. The average final dose after 12 weeks of treatment was 3.4 tablets per meal. Although there was decrease in serum phosphorus, in the absence of control group the true magnitude of effect is uncertain.The data presented in Table demonstrate the efficacy of calcium acetate in the treatment of hyperphosphatemia in end-stage renal disease patients. The effects on serum calcium levels are also presented.Table 2: Average Serum Phosphorous and Calcium Levels at Pre-Study, Interim, and Study Completion Time pointsParameterPre-StudyWeek b Week 8Week 12p-value Phosphorous (mg/dL) 7.4 +- 0.175.9 +- 0.165.6 +- 0.175.2 +- 0.17<=0.01Calcium8.9 +- 0.099.5 +- 0.109.7 +- 0.109.7 +- 0.10<=0.01a Values expressed as mean +- SE. Ninety-one patients completed at least weeks of the study. ANOVA of difference in values at pre-study and study completion. There was 30% decrease in serum phosphorus levels during the 12-week study period (p<0.01). Two-thirds of the decline occurred in the first month of the study. Serum calcium increased 9% during the study mostly in the first month of the study.Treatment with the phosphate binder was discontinued for patients from the open-label study, and those patients whose serum phosphorus exceeded 5.5 mg/dL were eligible for entry into double-blind, placebo-controlled, cross-over study. Patients were randomized to receive calcium acetate or placebo, and each continued to receive the same number of tablets as had been individually established during the previous study. Following weeks of treatment, patients switched to the alternative therapy for an additional weeks.The phosphate binding effect of calcium acetate is shown in the Table 3. Table 3: Serum Phosphorous and Calcium Levels at Study Initiation and After Completion of Each Treatment ArmParameterPre-StudyPost Treatmentp-value Calcium AcetatePlaceboPhosphorous (mg/dL) 7.3 +- 0.185.9 +- 0.247.8 +- 0.22<0.01Calcium (mg/dL)a8.9 +- 0.119.5 +- 0.138.8 +- 0.12<0.01a Values expressed as mean +- SEM ANOVA of calcium acetate vs. placebo after weeks of treatment. Overall, weeks of treatment with calcium acetate statistically significantly (p<0.01) decreased serum phosphorus by mean of 19% and increased serum calcium by statistically significant (p<0.01) but clinically unimportant mean of 7%.. 16 HOW SUPPLIED/STORAGE AND HANDLING. Calcium Acetate capsules USP, 667 mg are hard gelatin capsules with blue opaque cap imprinted with SUVEN in white color ink and white opaque body imprinted with 667 blue color ink. Each capsule contains 667 mg calcium acetate (anhydrous Ca(CH 3COO) 2; MW=158.17 grams) equal to 169 mg (8.45 mEq) calcium. NDC 16571-813-20 Bottles of 200 with child-resistant closure. STORAGE. Store at 20-25C (68-77F); excursions permitted to 15 to 30C (59 to 86F) [See USP Controlled Room Temperature].. 17 PATIENT COUNSELING INFORMATION. Inform patients to take calcium acetate capsules with meals, adhere to their prescribed diets, and avoid the use of calcium supplements including nonprescription antacids. Inform the patients about the symptoms of hypercalcemia see Warnings and Precautions (5.1) and Adverse Reactions (6.1)]. Advise patients who are taking an oral medication where reduction in the bioavailability of that medication would have clinically significant effect on its safety or efficacy to take the drug one hour before or three hours after calcium acetate capsules. Manufactured by:. Suven Pharmaceuticals Limited, Pashamylaram, Telangana, 502307, India ML No: 24/MD/AP/2009/F/CC Distributed by:Rising Pharma Holdings, Inc. East Brunswick, NJ 08816Lb50318-3-00.

SPL UNCLASSIFIED SECTION.

Manufactured by:. Suven Pharmaceuticals Limited, Pashamylaram, Telangana, 502307, India ML No: 24/MD/AP/2009/F/CC Distributed by:Rising Pharma Holdings, Inc. East Brunswick, NJ 08816Lb50318-3-00.

STORAGE AND HANDLING SECTION.

STORAGE. Store at 20-25C (68-77F); excursions permitted to 15 to 30C (59 to 86F) [See USP Controlled Room Temperature].

USE IN SPECIFIC POPULATIONS SECTION.

8 USE IN SPECIFIC POPULATIONS. 8.1 PregnancyPregnancy Category CCalcium acetate capsules contains calcium acetate. Animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. Patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment see Warnings and Precautions (5.1)]. Maintenance of normal serum calcium levels is important for maternal and fetal well-being. Hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. Calcium acetate treatment, as recommended, is not expected to harm fetus if maternal calcium levels are properly monitored during and following treatment. 8.2 Labor and DeliveryThe effects of calcium acetate on labor and delivery are unknown. 8.3 Nursing MothersCalcium acetate is excreted in human milk. Human milk feeding by mother receiving calcium acetate is not expected to harm an infant, provided maternal serum calcium levels are appropriately monitored. 8.4 Pediatric UseSafety and effectiveness in pediatric patients have not been established. 8.5 Geriatric UseClinical studies of calcium acetate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

WARNINGS AND PRECAUTIONS SECTION.

5 WARNINGS AND PRECAUTIONS. 5.1 HypercalcemiaPatients with end stage renal disease may develop hypercalcemia when treated with calcium, including calcium acetate. Avoid the use of calcium supplements, including calcium based nonprescription antacids, concurrently with calcium acetate. An overdose of calcium acetate may lead to progressive hypercalcemia, which may require emergency measures. Therefore, early in the treatment phase during the dosage adjustment period, monitor serum calcium levels twice weekly. Should hypercalcemia develop, reduce the calcium acetate dosage, or discontinue the treatment, depending on the severity of hypercalcemia.More severe hypercalcemia (Ca >12 mg/dL) is associated with confusion, delirium, stupor and coma. Severe hypercalcemia can be treated by acute hemodialysis and discontinuing calcium acetate therapy.Mild hypercalcemia (10.5 to 11.9 mg/dL) may be asymptomatic or manifest as constipation, anorexia, nausea, and vomiting. Mild hypercalcemia is usually controlled by reducing the calcium acetate dose or temporarily discontinuing therapy. Decreasing or discontinuing Vitamin therapy is recommended as well.Chronic hypercalcemia may lead to vascular calcification and other soft-tissue calcification. Radiographic evaluation of suspected anatomical regions may be helpful in early detection of soft tissue calcification. The long-term effect of calcium acetate on the progression of vascular or soft tissue calcification has not been determined.Hypercalcemia (>11 mg/dL) was reported in 16% of patients in 3-month study of solid dose formulation of calcium acetate; all cases resolved upon lowering the dose or discontinuing treatment. Maintain the serum calcium-phosphorus (Ca P) product below 55 mg2/dL2. 5.2 Concomitant Use with MedicationsHypercalcemia may aggravate digitalis toxicity.